Henshaw Capital’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Henshaw Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-269,120	Closed	-$8.94M	–	307
2017 Q2	$8.94M	Hold	269,120	–	–	0.94%	39
2017 Q1	$8.64M	Sell	269,120 -6,856	-2%	-$234K	0.94%	40
2016 Q4	$10M	Buy	275,976 +954	+0.3%	+$38.1K	1.18%	35
2016 Q3	$12.7M	Sell	275,022 -4,993	-2%	-$261K	1.56%	27
2016 Q2	$14.1M	Sell	280,015 -992	-0.4%	-$52.8K	1.83%	21
2016 Q1	$15M	Buy	+281,007	New	+$16.5M	2%	19

Other funds holding TEVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Henshaw Capital's TEVA Position: Q3 2017 in Review

Henshaw Capital sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2017, closing a stake of 269,120 shares — an estimated $8.94M sold.

Henshaw Capital first reported a position in TEVA in Q1 2016 and held it in 6 quarters. The position peaked at $15M in Q1 2016. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Henshaw Capital reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2017 after selling out during the quarter.
Henshaw Capital sold 269,120 Teva Pharmaceutical Industries Limited shares in Q3 2017, an estimated $8.94M.
Henshaw Capital first reported a position in Teva Pharmaceutical Industries Limited in Q1 2016 and held it in 6 quarters.
Henshaw Capital's Teva Pharmaceutical Industries Limited position peaked at $15M in Q1 2016.
537 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2017.

Based on Henshaw Capital's 13F filing for Q3 2017, filed 28 May 2026.